Elicio Therapeutics Files 8-K on Equity Sales
Ticker: ELTX · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, filing
TL;DR
Elicio Therapeutics filed an 8-K for unregistered equity sales. Watch for dilution.
AI Summary
Elicio Therapeutics, Inc. filed an 8-K on March 5, 2025, reporting on unregistered sales of equity securities. The company, formerly known as Angion Biomedica Corp., is based in Boston, MA, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates potential new equity issuance, which could impact share dilution and the company's capital structure.
Risk Assessment
Risk Level: medium — Unregistered equity sales can sometimes signal financial distress or dilutionary financing, requiring closer examination.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Angion Biomedica Corp. (company) — Former company name
- March 5, 2025 (date) — Date of report
- Boston, Massachusetts (location) — Principal executive offices
- 001-39990 (other) — Commission File Number
FAQ
What type of equity securities were sold in the unregistered offering?
The filing does not specify the type of equity securities sold in the unregistered offering.
Were there any specific dollar amounts associated with these unregistered sales?
The filing does not disclose specific dollar amounts for the unregistered sales of equity securities.
What is the purpose of the unregistered sale of equity securities?
The filing does not state the specific purpose for the unregistered sale of equity securities.
Who were the purchasers in this unregistered equity sale?
The filing does not identify the purchasers of the unregistered equity securities.
When did the event triggering this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on March 5, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 regarding Elicio Therapeutics, Inc. (ELTX).